Ocular Therapeutix Inc Stock News

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to red...

BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025.

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Analyst/Investor Day September 30, 2025 2:00 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Nadia Waheed - Chief Medical Officer Jeffrey Heier, - Chief Scientific Officer Namrata Saroj - Chief Business Officer Jay Robins Peter Kaiser - Chief Development Officer William Slattery - Vice President of Investor Relations Confere...

BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, be...

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Presentation Unknown Analyst Well, welcome Pravin. Great to have you here.